Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

Intra-Cellular Therapies, Inc. (ITCI.O)

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date	Stock Price (US$)	Price Target (US$)	Rating
2021-08-20	29.34	-	No Rating
2022-06-13	53.07	75.00	Buy
2022-10-20	44.71	70.00	Buy
2023-03-28	55.73	74.00	Buy
2023-06-30	63.32	80.00	Buy
2023-08-04	58.52	81.00	Buy
2024-02-23	70.16	85.00	Buy
2024-06-25	72.42	83.00	Neutral
2024-08-07	73.63	79.00	Neutral
2024-11-18	82.47	87.00	Neutral

Disclosures

UBS Securities LLC makes a market in the securities and/or ADRs of this company.
UBS holds a long or short position of 0.5% or more of the listed shares of this company.

Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day.